Portfolio
Portfolio

Achilles Therapeutics

Developing the next generation TIL therapies for solid tumors

Developing the next generation TIL therapies for solid tumors
Achilles Therapeutics is a biopharmaceutical company developing personalized Tumor Infiltrating Lymphocyte (TIL) therapies targeting clonal neoantigens: protein markers unique to each individual that are present on the surface of all the patient’s cancer cells.

  • CEO Iraj Ali
  • Industry Biotech